The Cost-Effectiveness of Bevacizumab for the Treatment of Advanced Ovarian Cancer in Canada | Zendy

M. Duong | Zendy; Elaine WRIGHT | Zendy; Lori Yin | Zendy; I. Martin-Nunez | Zendy; Prafull Ghatage | Zendy; Michael FungKeeFung | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Cost-Effectiveness of Bevacizumab for the Treatment of Advanced Ovarian Cancer in Canada

Author(s) -

M. Duong,

Elaine WRIGHT,

Lori Yin,

I. Martin-Nunez,

Prafull Ghatage,

Michael FungKeeFung

Publication year - 2016

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.23.3139

Subject(s) - medicine , bevacizumab , oncology , ovarian cancer , quality adjusted life year , incremental cost effectiveness ratio , cost effectiveness , population , randomized controlled trial , progression free survival , cost effectiveness analysis , chemotherapy , quality of life (healthcare) , cancer , risk analysis (engineering) , environmental health , nursing

The overall survival (os) analysis of the icon7 trial demonstrated that frontline ovarian cancer patients with a high risk of progression (stage iii suboptimally debulked, and stage iii or iv with unresectable disease) benefited from the addition of bevacizumab to standard chemotherapy compared with standard chemotherapy alone. The objective of the present study was to investigate the cost-effectiveness, from a Canadian publicly funded perspective, of adding bevacizumab to frontline treatment of ovarian cancer at high risk of progression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research